Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15352862 | 0.82 | AR (0.43) | ARMAOBMAOANQO1NPC1 | |
| SCHEMBL10794491 | 0.80 | MAOA (0.49) | ARMAOANQO1HPGDSMN1; SMN2 | |
| SCHEMBL15842670 | 0.72 | ALDH1A1 (0.53) | MAOAGAAMGAMSIMGAM2 | |
| SCHEMBL14227248 | 0.72 | CA1 (0.46) | ARMAOBMAOAGAAMGAM | |
| SCHEMBL15842746 | 0.71 | AR (0.50) | ARMAOBMAOANQO1NPC1 | |
| SCHEMBL10790857 | 0.68 | HSD17B3 (0.51) | ARMAOAHSD17B3NPC1HPGD | |
| SCHEMBL9282004 | 0.68 | MAOA (0.63) | ARMAOAGAAMGAMSI | |
| SCHEMBL5342252 | 0.67 | CA9 (0.55) | ARGAAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL29854712 | 0.67 | AR (0.58) | ARGAANPC1HPGDRAB9A | |
| SCHEMBL13717866 | 0.67 | AR (0.58) | ARGAANPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153828-B2 | Optical molecular sensors for cytochrome P450 activity | Life Technologies Corporation (US) | 2012-04-10 | — | — | US | claimed |
| EP-1597602-A4 | SOLID PHASE SEQUENCING | GE HEALTHCARE BIO SCIENCES (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7393640-B2 | Terminal-phosphate-labeled nucleotides with new linkers | GE HEALTHCARE BIO-SCIENCES CORP. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1592779-A4 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES WITH NEW LINKERS | GE HEALTHCARE BIO SCIENCES (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1590475-A4 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE | GE HEALTHCARE BIO SCIENCES (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7223541-B2 | Terminal-phosphate-labeled nucleotides and methods of use | GE HEALTHCARE BIO-SCIENCES CORP. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7052839-B2 | Terminal-phosphate-labeled nucleotides and methods of use | AMERSHAM BIOSCIENCES CORP (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1597602-A2 | SOLID PHASE SEQUENCING | Amersham Biosciences Corp. (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1592779-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES WITH NEW LINKERS | Amersham Biosciences Corp. (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1590475-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE | Amersham Biosciences Corp. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040241716-A1 | Terminal-phosphate-labeled nucleotides with new linkers | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004072297-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE | AMERSHAM BIOSCIENCES CORP (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004071155-A2 | SOLID PHASE SEQUENCING | AMERSHAM BIOSCIENCES CORP (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072238-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES WITH NEW LINKERS | AMERSHAM BIOSCIENCES CORP (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040152119-A1 | Solid phase sequencing | GE HEALTHCARE BIO-SCIENCES CORP. | 2004-08-05 | — | — | US | disclosed |
| EP-1421212-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE | Amersham Biosciences Corp. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030162213-A1 | Terminal-phosphate-labeled nucleotides and methods of use | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-08-28 | — | — | US | disclosed |
| US-20030077610-A1 | Terminal-phosphate-labeled nucleotides and methods of use | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-04-24 | — | — | US | disclosed |
| WO-2003020984-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE | AMERSHAM BIOSCIENCES CORP (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030077610-A1 | Terminal-phosphate-labeled nucleotides and methods of use | RNGTT, DNTT, PNP | AR 4366/4885MAOB 2287/4885MAOA 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.